8-KMaterial AgreementsExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Material Agreement (Jun 24, 2005)

Filed June 24, 2005For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) announced on June 24, 2005, that it entered into an agreement with Lighthouse Capital Partners V, L.P. to amend its existing Loan and Security Agreement. This amendment is significant for investors as it extends the period during which Alnylam can draw down funds under its line of credit. Previously set to expire on June 30, 2005, the company can now access these funds until January 1, 2006, provided certain conditions are met. This extension provides Alnylam with additional financial flexibility and runway to fund its operations and development activities. The company will pay a fee to Lighthouse Capital Partners related to the remaining commitment amount as of October 1, 2005. This filing highlights Alnylam's proactive management of its financing arrangements to support its ongoing business objectives.

Key Highlights

  • 1Alnylam Pharmaceuticals amended its Loan and Security Agreement with Lighthouse Capital Partners.
  • 2The amendment extends the drawdown period for Alnylam's line of credit from June 30, 2005, to January 1, 2006.
  • 3This extension provides Alnylam with additional financial runway and flexibility.
  • 4Alnylam will pay a fee to Lighthouse Capital Partners based on the remaining commitment amount as of October 1, 2005.
  • 5The company continues to manage its financing to support its operational and development needs.

Frequently Asked Questions

The main purpose of this 8-K filing is to announce an amendment to Alnylam Pharmaceuticals' existing Loan and Security Agreement with Lighthouse Capital Partners. This amendment primarily extends the timeframe within which Alnylam can draw funds from its line of credit.

The amendment significantly improves Alnylam's access to capital by extending the deadline for drawing down funds under its line of credit from June 30, 2005, to January 1, 2006. This provides the company with more time and financial flexibility to manage its operations and development programs.

Alnylam Pharmaceuticals has agreed to pay a fee to Lighthouse Capital Partners. This fee is calculated as three-quarters of one percent (0.75%) of the dollar amount of the commitment remaining as of October 1, 2005.

No, this filing does not represent a new financing or debt issuance. It is an amendment to an existing Loan and Security Agreement, extending the drawdown period of a previously established line of credit.